Clinical Trials Logo

Systemic Embolism clinical trials

View clinical trials related to Systemic Embolism.

Filter by:
  • None
  • Page 1

NCT ID: NCT05963698 Recruiting - Atrial Fibrillation Clinical Trials

The Fourth Left Atrial Appendage Occlusion Study

LAAOS-4
Start date: November 30, 2023
Phase: N/A
Study type: Interventional

LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.

NCT ID: NCT05540587 Recruiting - Stroke Clinical Trials

Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

ERTEMIS
Start date: May 20, 2022
Phase: Phase 2
Study type: Interventional

This study aims to compare the efficacy and safety of the edoxaban and the warfarin in atrial fibrillation patients with mitral stenosis. The study design is a multicenter, randomized, open-label, investigator initiated phase 2 trial. The patients were randomly assigned to Edoxaban or Warfarin groups. Primary outcome was a composite of stroke and systemic arterial thromboembolism. The safety outcome was major bleeding.

NCT ID: NCT05478304 Recruiting - Ischemic Stroke Clinical Trials

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

LeAAPS
Start date: January 25, 2023
Phase: N/A
Study type: Interventional

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

NCT ID: NCT04808934 Withdrawn - Stroke Clinical Trials

NOAC Portuguese Real World Study

Start date: June 1, 2020
Phase:
Study type: Observational

To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists

NCT ID: NCT02889562 Completed - Stroke Clinical Trials

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Start date: September 2016
Phase: Phase 2/Phase 3
Study type: Interventional

In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified. Patients with persistent atrial fibrillation (>12 hours) or recurrent sustained atrial fibrillation (>2 episodes of atrial fibrillation lasting longer than 30 minutes) will be candidates for inclusion. Upon meeting study inclusion and exclusion criteria, and after informed consent, patients will be randomized to either the standard of care (warfarin per protocol) or apixaban arms of the trial. Routine postoperative care after CABG will occur in both groups. Upon discharge, anticoagulation in both groups will be managed by the anticoagulation clinic. Patients will be followed for 30 days after surgery.

NCT ID: NCT02478294 Completed - Stroke Clinical Trials

LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke

5A
Start date: January 2013
Phase:
Study type: Observational

This cohort study aims to evaluate thoracoscopic left atrial appendage excision plus atrial fibrillation ablation versus oral anticoagulants for the prevention of stroke and non-central nervous systemic embolism in patients with atrial fibrillation and thromboembolism.